ライフサイエンスコーパス: periampullary

1 underwent pancreaticoduodenal resection for periampullary adenocarcinoma at The Johns Hopkins Hospit

2 IAT recipients had malignancy (pancreatic or periampullary adenocarcinoma in 14).

3 ltivariate analysis of the 443 patients with periampullary adenocarcinoma indicated that the most pow

4 ed overall survival in ampullary relative to periampullary adenocarcinoma is due in part to a signifi

5 Among patients with periampullary adenocarcinoma treated by pancreaticoduode

6 April 1996 and June 2001, 299 patients with periampullary adenocarcinoma were enrolled in a prospect

7 il 1996 and December 1997, 114 patients with periampullary adenocarcinoma were enrolled in an ongoing

8 Of the 242 patients with resected periampullary adenocarcinoma, 149 (62%) were pancreatic

9 Among patients with resected periampullary adenocarcinoma, adjuvant chemotherapy, com

10 cause their final pathology failed to reveal periampullary adenocarcinoma, leaving 294 patients for a

11 xists regarding the benefit of resection for periampullary adenocarcinoma, particularly for pancreati

12 frozen section) of margin-negative resected periampullary adenocarcinoma, patients were randomized t

13 perative verification of completely resected periampullary adenocarcinoma, the patients were randomiz

14 ore years ago by pancreaticoduodenectomy for periampullary adenocarcinoma.

15 Morphologic subtypes of periampullary adenocarcinomas (i.e., pancreatobiliary or

16 rs associated with survival in patients with periampullary adenocarcinomas and to compare survival be

17 In contrast to many other solid tumors, periampullary adenocarcinomas exhibited more frequent ge

18 ations using Affymetrix SNP 6.0 arrays in 60 periampullary adenocarcinomas from Oslo University Hospi

19 Patients with periampullary adenocarcinomas have widely variable survi

20 prognosticator of survival in patients with periampullary adenocarcinomas than tumor anatomic locati

21 Patients with periampullary adenocarcinomas undergo the same resection

22 Survival of patients with periampullary adenocarcinomas was compared by the Kaplan

23 er, there have been no randomized trials for periampullary adenocarcinomas.

24 vival for patients with pancreatic and other periampullary adenocarcinomas.

25 for some patients with pancreatic and other periampullary adenocarcinomas.

26 71; 11%), neuroendocrine tumor (n = 31; 5%), periampullary adenoma (n = 21; 3%), cystadenocarcinoma (

27 n organs have received particular attention, periampullary and pancreatic incidentalomas (PIs) remain

28 Incidentally discovered periampullary and pancreatic masses comprise a substanti

29 Periampullary bleeding is an uncommon cause of upper gas

30 Spontaneous, non-iatrogenic periampullary bleeding is extraordinarily rare with only

31 is is the first reported case of spontaneous periampullary bleeding successfully treated with APC.

32 Between 25% and 75% of patients with periampullary cancer who undergo exploratory surgery wit

33 t laparotomy in patients with pancreatic and periampullary cancer with resectable disease based on CT

34 t-effective in pancreatic cancer (but not in periampullary cancer), when laparotomy following diagnos

35 e only curative treatment for pancreatic and periampullary cancer, but many patients undergo unnecess

36 in 10% to 20% of patients with unresectable periampullary cancer.

37 The distribution of periampullary cancers by site in the reoperative group u

38 r to the 65%, 14%, 16% and 5% for resectable periampullary cancers found in the primary surgery group

39 tients are referred to tertiary centers with periampullary carcinoma after their tumors were deemed u

40 mes of patients undergoing reexploration for periampullary carcinoma at a high-volume center.

41 ate that patients undergoing reoperation for periampullary carcinoma have similar resectability, peri

42 tomy and/or palliative surgery for suspected periampullary carcinoma underwent reexploration.

43 exploratory laparotomy to have unresectable periampullary carcinoma.

44 ergoing surgical palliation for unresectable periampullary carcinoma.

45 d prospectively for patients presenting with periampullary carcinomas to the Memorial Sloan-Kettering

46 Telomerase activity is common in periampullary carcinomas.

47 d April 2003, 1595 patients underwent PD for periampullary disease (392 benign, 1203 malignant).

48 coduodenectomy (PD) for benign and malignant periampullary disease.

49 testine (especially the clinically important periampullary duodenum), ursodeoxycholate had equal effi

50 omerase activity was upregulated in 26 of 33 periampullary malignancies (79%): 17 of 21 pancreatic ad

51 y 1994 and October 1998, 194 patients with a periampullary malignancy underwent exploratory surgery w

52 e ampulla of Vater is the second most common periampullary malignancy.

53 ed safely during pancreaticoduodenectomy for periampullary malignant tumors.

54 Five (1.7%) of 288 patients with other periampullary neoplasms also had a deleterious germline

55 noma, 288 patients with other pancreatic and periampullary neoplasms, and 51 patients with non-neopla

56 s affected by middle-distal obstruction from periampullary neoplasms, in which preoperative drainage

57 pulla of Vater is improved relative to other periampullary neoplasms.

58 s) presented with an incidental finding of a periampullary or pancreatic mass.

59 urrent management of jaundiced patients with periampullary or proximal bile duct neoplasms who are ca

60 uodenectomy (PD) or major hepatectomy due to periampullary or proximal bile duct neoplasms.

61 ectomy for adenocarcinoma of the pancreas or periampullary region over a 3.5-year period were entered

62 ith NF-1, the carcinoids were located in the periampullary region.

63 nant and benign diseases of the pancreas and periampullary region.

64 nant and benign diseases of the pancreas and periampullary region.

65 ant and benign disorders of the pancreas and periampullary region.

66 nts with malignant tumors of the pancreas or periampullary region.

67 ectomy for tumors of the pancreatic head and periampullary region.

68 Study Group for Pancreatic Cancer (ESPAC)-3 periampullary trial, an open-label, phase 3, randomized

69 adenocarcinoma (142 patients, 92%) or other periampullary tumors (12 patients, 8%).

70 reas, and long-term survival rates for other periampullary tumors are approximately 40%.

71 Periampullary tumors are neoplasms that arise in the vic

72 n diagnostics, less than 5% of patients with periampullary tumors experience an overall survival of f

73 Poorly differentiated periampullary tumors had significantly higher telomerase

74 l pancreatectomies for primary pancreatic or periampullary tumors were performed between October 2001

75 Fresh specimens of 62 periampullary tumors were snap-frozen in liquid nitrogen

76 identifies potential prognostic markers for periampullary tumors, the genetic characterization of wh

77 In periampullary tumors, the highest rates of resection and